ArticleNeuro-oncology practice2025
Characteristics and outcome of patients with brain metastases from colorectal cancer.
Article in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite a generally poor prognosis of patients with brain metastases of colorectal cancer (CRC-BM), local treatment of BM might be beneficial in selected patients. The aim of this study was to characterize patient and clinicopathological characteristics of CRC-BM and to identify patients who benefit most from local treatment of CRC-BM. Methods: In this retrospective cohort study, clinicopathological characteristics, including treatment response and survival, were collected from 100 patients who were treated for CRC-BM at the Netherlands Cancer Institute between 2001 and 2021. All analyses were performed using SPSS. Results: Median overall survival (OS) from CRC diagnosis and diagnosis of BM was 47.3 and 5.2 months, respectively. Median brain metastasis-free interval (BMFI) was 39.0 months. Median OS of patients with metachronous extracranial metastases (ECM) and subsequent BM was 5.7 months compared to 2.8 months in patients with synchronous ECM and subsequent BM ( Conclusions: Although the development of BM in patients with CRC is a late event resulting in a poor prognosis, outcome improved over time. OS was significantly longer in patients who still have systemic treatment options. This can be taken into account in the decision for local treatment of patients with CRC-BM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.